Is stereotactic ablative radiotherapy (SABR) clinically suitable in early stage non-small cell lung cancer (NSCLC) patients with WHO performance status (PS) 3?
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI